A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

Launched by SHANGHAI TONG REN HOSPITAL · Feb 3, 2020

Keywords

ClinConnect Summary

This clinical trial is studying two different doses of a medication called ticagrelor, taken with aspirin, to see which is better at preventing serious heart or brain problems after patients have received a special type of heart stent called a drug-eluting stent. The study focuses on patients in China who have experienced acute coronary syndrome (ACS), a condition where the blood supply to the heart is suddenly reduced. Researchers want to find out if taking a lower dose of ticagrelor (60 mg) is just as safe and effective as a standard dose (90 mg) for these patients over the course of one year.

To participate in this study, you need to be at least 18 years old and have already had a successful procedure to insert a drug-eluting stent for ACS. It's important that you understand the study and agree to participate before starting. However, this trial isn't for everyone. If you are a woman who might become pregnant, have certain serious medical conditions, or have a history of significant bleeding or strokes, you may not be eligible. If you join the study, you will be monitored closely to ensure your safety and to help the researchers learn more about the best way to prevent further heart and brain issues after stent placement.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject must be at least 18 years of age
• • 2. Patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for acute coronary syndrome
• • 3. Subject understand the study requirements and the treatment procedures and provided informed consent before the procedure
• Exclusion Criteria:
• • 1. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
• • 2. Active bleeding
• • 3. Known hypersensitivity or contraindication to study medications
• • 4. Non-cardiac co-morbid conditions are present with life expectancy \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment).
• • 5. Subjects with Cerebral hemorrhage history
• • 6. Subjects with stroke history in half a year
• • 7. subjects with malignant tumor
• • 8. subjects with whom oral anticoagulants are needed